Kenya and Zimbabwe rolls out new HIV prevention drug lenacapavir
Kenya has officially launched the rollout of Lenacapavir, a revolutionary long-acting injectable drug for HIV prevention, becoming the first country in East Africa to offer this twice-yearly, game-changing treatment. The national rollout, which began in late February 2026, aims to significantly reduce new HIV infections, especially among high-risk groups, by providing an alternative to daily oral medication. The Drug: Lenacapavir (often referred to as LEN) is a long-acting injectable pre-exposure prophylaxis (PrEP) administered once every six months. Studies show the drug can reduce HIV transmission risk by more than 99.9%, making it a highly effective tool for HIV-negative individuals. The initial rollout involves 21,000 doses, targeting 15 high-burden counties, including Nairobi, Mombasa, Kisumu, Homa Bay, and Siaya. The medication will be provided free of charge in public facilities, with the government having negotiated a price of KSh 7,800 per dose (down from an ...